Delivery systems for penetration enhancement of peptide and protein drugs: design considerations☆
Introduction
Optimizing the delivery system to maximize the extent of peptide and protein absorption has not received as much attention as the use of penetration enhancers. The majority of delivery systems that have been investigated to date are those designed to protect peptide and protein drugs from the luminal proteases in the gastrointestinal tract [1], [2]. More recent applications of delivery systems seem to focus on their capability of being retained at the site of absorption or being actively phagocytosed by the epithelial cells. Of these systems, nano- and microparticles as well as nano- and microcapsules have received the most attention to date.
An impressive insulin bioavailability of 30% has been achieved following the administration of human monocomponent insulin in 45 μm lyophilized dextran starch microspheres to the nasal cavity of anesthetized rats [3]. Peak serum insulin concentration was achieved within 7–10 min, leading to maximal decrease in blood glucose level 20–30 min thereafter. This early peak time suggests that prolonged retention of the microspheres in the nasal cavity reported by Illum et al. [4] is not an important contributing factor in the enhancement of nasal insulin absorption. A more plausible mechanism is dehydration of the underlying mucus to which the microspheres adhered, followed by rapid release of insulin from the microspheres simultaneously with shrinkage of the underlying epithelial cells and opening of the tight junctions. At an insulin dose of 1 U kg−1, an optimal microsphere load was attained at 3–7 mg kg−1 over the range of 2.35–10 mg kg−1 [5], suggesting that a proper balance between the degree of dehydration and solubility of insulin in the residual moisture in the mucus was essential to the extent of absorption enhancement attained. Differences in insulin release rate, as indicated by the time required to deplete 90% of the insulin load (t90), did not affect blood glucose kinetics in rats following microsphere administration. The time course of hypoglycemia was the same whether the t90 was 10 or 60 min.
A lower bioavailability, 2.7%, was obtained for human growth hormone (hGH) when administered to the nasal cavity of the sheep in the same dextran starch microsphere system (0.9 IU kg−1) [6]. Poor absorption was attributed to the low solubility of human growth hormone (18 mg ml−1). Its bioavailability was, however, increased to 14.4% upon incorporation of l-α-lysophosphatidylcholine at a dose of 0.2 mg kg−1 into the delivery system. This was accompanied by a shortening of the peak time in plasma from 120 to 60 min. The long-term safety of microsphere administration to the nasal cavity of the rat has been discussed in the review by Edman and Björk in this theme volume (see first article in the subsequent issue).
Orally administered insulin has been reported to be absorbed from polyisobutylcyanoacrylate nanocapsules, mean size 220 nm, following intragastric administration in diabetic rats [7]. Fasted glucose levels were lowered to 50–60% by day 2 and were maintained for 6–20 days in a dose-dependent manner over the range of 12.5 and 50 U kg−1 (Fig. 1). The investigators proposed that the nanocapsules passed through the epithelial mucosa via the paracellular pathway and were then transported to the liver, where insulin acts, even though the size of the nanocapsules exceeds the pore size of the portal capillaries (60–100 nm) [8]. While this study has raised the interesting possibility of using nanocapsules to circumvent the proteolytic and penetration barriers to orally administered peptide and protein drugs, it has not yet addressed the crucial issues of absorption enhancement mechanisms, biological fate of the nanocapsules and long-term safety.
Another application of orally administered microparticulate system is in targeting to the gut-associated lymphoid tissues represented by the Peyer’s patches [9]. This possibility was suggested in a study by Eldridge et al. [9], who administered 20 mg of microspheres containing the fluorescent dye, Coumarin-6, to non-anesthetized mice. At 48 h, the mice were killed and three representative Peyer’s patches, together with the first mesenteric lymph node proximal to the appendix and the spleen, were excised for microscopic observation. The number of absorbed microspheres was counted in frozen sections using a fluorescence microscope. The percentage of ingested dose was not determined, however.
Of the microspheres investigated, only those composed of polystyrene, poly(methylmethacrylate), poly(hydroxybutyrate), poly(d,l-lactide), poly(l-lactide) and poly(d,l-lactide-coglycolide) were absorbed into the Peyer’s patches of the small intestine, while those composed of ethyl cellulose, cellulose acetate hydrogen phthalate and cellulose triacetate were not. Microsphere uptake occurred only in the Peyer’s patches and was restricted to those microspheres up to 10 μm in diameter. Fig. 2 shows the tissue distribution of 50:50 poly(d,l-lactide-coglycolide) microspheres as a function of time. As can be seen, the total number of microspheres within the three Peyer’s patches reached a maximum on day 4 and then decreased as the particles smaller than 5 μm were removed from the tissue by the efferent lymphatics. By contrast, microspheres of diameter greater than 5 μm were retained in the Peyer’s patches even on day 35. In the mesenteric lymph nodes and the spleen, the number of microspheres reached a peak on day 7 for those smaller than 5 μm and on day 14 for those greater than 5 μm in diameter.
Following primary, secondary and tertiary oral immunization with 100 mg doses of microencapsulated or soluble staphylococcal enterotoxin B vaccine, plasma anti-toxin IgG antibody levels were shown to be several thousand times significantly higher with toxoid-containing poly(d,l-lactide-coglycolide) microspheres of a mean diameter of 4 μm [9]. A separate study by Ebel [10] using polystyrene latex particles, 2.65 μm in diameter, indicated that only 0.01% of doses in the 106–108 particle number range were absorbed in young adult female BALB/c mice given a single oral gavage. LeFevre et al. [11] found that the number of rhodamine B-labeled polystyrene latex particles, 1.8±0.13 μm, absorbed beyond the Peyer’s patches remained small even after gavage 5 days per week for 25 days. While such low absorption efficiency may be adequate for oral immunization, it would seem to preclude delivery of systemically active peptide and protein drugs.
The purpose of this paper is to discuss the challenges to be met in designing delivery systems for maximizing peptide and protein drug absorption from mucosal routes. The focus will be on the oral and pulmonary routes of administration.
Section snippets
Design considerations of oral delivery systems for peptide and protein drugs
Identifying a region in the intestine that favors peptide and protein absorption is a crucial step in the design of oral delivery systems for peptide and protein drugs. Regional variations in the penetration barriers to peptides may result in regional differences in their absorption. For instance, M-cells located on the dome epithelium of gut-associated lymphoid tissue are known to be capable of sampling macromolecular antigens from the lumen through an endocytotic pathway [12]. Absorptive
Design considerations of pulmonary delivery systems for peptide and protein drugs
Peptide and protein drugs including leuprolide [217], [218], oxytocin [219], insulin [220], [221], human growth hormone [222] and human IgG [223] have been shown to reach the systemic circulation following pulmonary administration. In the case of leuprolide, intratracheal administration in beagle dogs yielded an absolute bioavailability of 36–38% [217]. An absolute bioavailability of 18% was observed in healthy volunteers following oral inhalation of leuprolide as a suspension aerosol [218]. It
Conclusion
The importance of the delivery system in determining the absorption efficiency of peptide and protein drugs from any mucosal route of administration cannot be ignored. In the oral and pulmonary routes of administration, the ideal delivery system is one that releases its contents only at the target region, independent of patient variables such as gastric emptying and intestinal transit in the oral route, and breath pattern, breath frequency and volume inhaled in the pulmonary route. An efficient
References (278)
- et al.
Enzymatic barriers to peptide and protein drug delivery
Protease inhibitors and penetration enhancers as approaches to modify peptide absorption
J. Control. Release
(1990)- et al.
Degradable starch microspheres as a nasal delivery system for insulin
Int. J. Pharm.
(1988) - et al.
Nasal administration of gentamicin using a novel microsphere delivery system
Int. J. Pharm.
(1988) - et al.
Characterization of degradable starch microspheres as a nasal delivery system for drugs
Int. J. Pharm.
(1990) - et al.
Investigation of the nasal absorption of biosynthetic human growth hormone in sheep-use of bioadhesive microsphere delivery system
Int. J. Pharm.
(1990) - et al.
New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier
Diabetes
(1988) - et al.
Ultrastructure of microvascular functional exchanges
- et al.
Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer’s patches
J. Control. Release
(1990) A method for quantifying particle absorption from the small intestine of the mouse
Pharm. Res.
(1990)
Intestinal uptake of fluorescent microspheres in young and aged mice
Proc. Soc. Exp. Biol. Med.
Quantitative determination of macromolecular transport rate across intestinal Peyer’s patches
Am. J. Physiol.
Transepithelial transport of epidermal growth factor by absorptive cells of suckling rat ileum
J. Clin. Invest.
Uptake and transepithelial transport of nerve growth factor in suckling rat ileum
J. Cell Biol.
A cytological study of intestinal absorption in the suckling rat
Am. J. Anat.
Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption
Ann. NY Acad. Sci.
Impaired absorption of egg vitamin B12 in postgastrectomy and achlorhydric patients
J. Lab. Clin. Med.
Colon-specific delivery of dexamethasone from a glucoside prodrug in the guinea pig
Pharm. Res.
Colon specific delivery from a glucoside prodrug in the guinea pig. Efficacy study
J. Control. Release
Development of a multiple unit drug delivery system for positioned release in the gastrointestinal tract
J. Control. Release
Absorption differences of ciprofloxacin along the human gastrointestinal tract determined using a remote control drug delivery device (HF-capsule)
Am. J. Med.
Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with hf-capsule
Br. J. Clin. Pharmacol.
Characterization of the oral absorption of β-lactam antibiotics. I. Cephalosporine: Determination of intrinsic membrane absorption parameters in the rat intestine in situ
Pharm. Res.
The absorption of piretanide from the gastro-intestinal tract is site-dependent
Eur. J. Clin. Pharmacol.
Investigation of drug absorption from the gastrointestinal tract of man. I. Metoprolol in the stomach, duodenum and jejunum
Br. J. Clin. Pharmacol.
A study of the absorption of diltiazem from distal parts of the gastrointestinal tract
Eur. J. Clin. Pharmacol.
Evidence of a specialized transport mechanism for the intestinal absorption of baclofen
Biopharm. Drug Disp.
The ileum is the major site of absorption of vitamin B12 analogues
Am. J. Gastroentol.
Passive and carrier-mediated intestinal absorption components of captopril
J. Pharm. Sci.
Evidence for site-specific absorption of a novel ACE inhibitor
Pharm. Res.
Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril
Pharm. Res.
Pharmacokinetics of oral cyclosporine A (Sandimmun) in healthy subjects
Eur. J. Clin. Pharmacol.
Absorption of cyclosporine from rabbit small intestine in situ
J. Pharm. Sci.
Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size
Pharm. Res.
Absorption of 1-deamino-8-d-arginine vasopressin from different regions of the gastrointestinal tract in rabbits
Acta Endocrinol.
Absorption of an aqueous solution of a new synthetic somatostatin analogue administered to man by gavage
Eur. J. Clin. Pharmacol.
Gastrointestinal mucus: synthesis, secretion and function
Mucus glycoprotein structure, gel formation and gastrointestinal mucus function
Assessment of gastrointestinal transit and drug absorption
β-d-Glucosiduronic acid conjugation by the mucosa of various organs
Nature
Active metabolism of the gastrointestinal wall
Functional anatomy of mucus-secreting cells
Adv. Exp. Med. Biol.
Bioysnthesis of mucus glycoproteins
Adv. Exp. Med. Biol.
Progress report: mucus and bicarbonate secretion in the stomach and their possible role in mucosal protection
Gut
Structure and function of mucus
Adv. Exp. Med. Biol.
Structure and function of gastrointestinal mucus
Hydration kinetics of exocytosed mucins in cultured secretory cells of the rabbit trachea: a new model
A 70,000 mol. weight protein isolated from purified pig gastric mucus glycoprotein by reduction of disulfide bridges and its implication in the polymer structure
Biochem. J.
Isolation and characterization of human and canine gastric mucosal glycoproteins and their degradation by proteases and acid hydrolases
Hoppe Seylers Z. Physiol. Chem.
Cited by (108)
Mesoporous silica nanoparticles: An emerging approach in overcoming the challenges with oral delivery of proteins and peptides
2023, Colloids and Surfaces B: BiointerfacesPeptide and protein delivery through carrageenan, alginic acid, agar, and myrrh
2023, Peptide and Protein Drug Delivery Using PolysaccharidesFormulation strategies to improve the efficacy of intestinal permeation enhancers
2021, Advanced Drug Delivery ReviewsIdentification and molecular mechanism of angiotensin-converting enzyme inhibitory peptides from Larimichthys crocea titin
2020, Food Science and Human WellnessBasic and recent advances in marine antihypertensive peptides: Production, structure-activity relationship and bioavailability
2019, Trends in Food Science and TechnologyCitation Excerpt :The pH of the stomach varies between 1.0 and 3.0, that of the duodenum between 6.0 and 6.5, and that of the large intestine between 5.5 and 7.0 (Van de Graaff, 1986). Thus, peptides’ absorption is limited by several factors such as the gastro-intestinal enzymes action and harsh degradative pH environment, especially in the stomach (Kompella & Lee, 2001). Nevertheless, it is commonly thought that short chain-length peptides are easily absorbed, which allows them to pass in their intact form, reach the bloodstream and therefore, their targets.
Bioavailability of nanotechnology-based bioactives and nutraceuticals
2019, Advances in Food and Nutrition Research
- ☆
The article was originally published in Advanced Drug Delivery Reviews 8 (1992) 115–162.